Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04745559 · ClinicalTrials.gov registry record · Phase 2
Optimizing Cellular and Humoral Immunity by Vaccinating With PCV13 Before and After CAR-T Therapy
A Phase 2 study of Follicular Lymphoma and Primary Mediastinal Large B-cell Lymphoma (PMBCL), sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Active
- Registry status
- Phase 2
- Development phase
- 26
- Enrollment target
- 1
- Study location
NCT04745559 is a Phase 2 study of Follicular Lymphoma and Primary Mediastinal Large B-cell Lymphoma (PMBCL) that is active but no longer recruiting, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 26 participants, below the 135-participant average among 89 other Follicular Lymphoma trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04745559, a Phase 2 study of Follicular Lymphoma and Primary Mediastinal Large B-cell Lymphoma (PMBCL), is active but no longer recruiting, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 26 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to evaluate whether receiving the pneumococcal 13-valent conjugate vaccine (PCV13) before and after CD19-targeted CAR T cell therapy will optimize cellular and humoral immunity to pneumococcus.
Conditions Studied
Interventions
- BIOLOGICAL Pneumococcal conjugate vaccine (PCV13)
- BIOLOGICAL CD19 targeted CAR T Cell Therapy
Study Locations (1)
Florida
- Moffitt Cancer Center - Tampa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2021-02-18 |
| Est. Completion | 2027-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04745559
The ClinicalTrials.gov registry entry for NCT04745559 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 135-participant average among 89 other Follicular Lymphoma trials with a reported enrollment target (81% lower). The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Follicular Lymphoma appearing as the primary indexed condition, and to 2 interventions - of which Pneumococcal conjugate vaccine (PCV13) is the first listed.
NCT04745559 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT04745559 about?
NCT04745559 is a clinical study titled "Optimizing Cellular and Humoral Immunity by Vaccinating With PCV13 Before and After CAR-T Therapy". The purpose of the study is to evaluate whether receiving the pneumococcal 13-valent conjugate vaccine (PCV13) before and after CD19-targeted CAR T cell therapy will optimize cellular and humoral immunity to pneumococcus.
What is the current status of trial NCT04745559?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 26 participants. The study started on 2021-02-18. Estimated completion is 2027-06.
What conditions does trial NCT04745559 study?
This clinical trial studies the following conditions: Follicular Lymphoma, Primary Mediastinal Large B-cell Lymphoma (PMBCL), Diffuse Large Cell Lymphoma, High Grade B-cell Lymphoma (HGBCL), Transformed Follicular Lymphoma (tFL).
What interventions are being tested in trial NCT04745559?
The interventions under investigation include: Pneumococcal conjugate vaccine (PCV13) (BIOLOGICAL), CD19 targeted CAR T Cell Therapy (BIOLOGICAL).
Who is sponsoring clinical trial NCT04745559?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04745559 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Follicular Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
RECRUITING · Phase 2
-
A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma
RECRUITING · Phase 2
-
Epcoritamab and Rituximab for First-line Follicular Lymphoma
RECRUITING · Phase 2
-
HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL
RECRUITING · Phase 2
-
Odronextamab in Low Tumor Volume Advanced FL
RECRUITING · Phase 2
-
Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma
RECRUITING · Phase 2
Explore more on PlainTrial
Follicular Lymphoma
All registered trials for this condition
Primary Mediastinal Large B-cell Lymphoma (PMBCL)
All registered trials for this condition
Florida
All trials with a study site in Florida
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.